Devika Proteins Ltd

Financial results and auditor opinion

• Unaudited standalone quarterly results for quarter ended June 30, 2026 approved, with Limited Review Report.
• Auditor’s Limited Review Report issued with unmodified opinion.
• Results prepared in Ind AS for quarter ended June 30, 2026.

Meeting Details

• Board meeting scheduled for 15 July 2026; time and venue not disclosed.

Key Agenda Items

• Consider unaudited standalone results for Q1 FY2026-27 and record Limited Review Report (quarter ended 30 June 2026).
• Any other matter with permission of the chair.

Other Notes

• No trading window closure period specified.

Demat/remat status

• No details on processing of dematerialisation/rematerialisation requests are provided.
• No confirmation of listing of dematerialised securities on stock exchanges is provided.
• No information on physical certificates being mutilated or cancelled or depository ownership update within timeline is provided.

ISIN change and ownership reshaping

• Capital reduction executed; erstwhile promoters' and promoter group holdings cancelled.
• Public shareholders' shareholding reduced pro rata under the approved resolution plan.
• Preferential allotment of equity shares to new promoter group and secured creditor.
• Old ISIN INE248C01013 replaced with new ISIN INE248C01021.
• New ISIN activated by NSDL and CDSL; activation letters enclosed.
• Activation live on 01 July 2026 per CDSL notice.
• Impact on ownership structure: shift to new promoter group and secured creditor.

FY26 standalone results

• 📊 Revenue from operations was Rs 4.77 lakh in Q4 FY26 versus Rs 2.97 lakh last year.
• 📊 Total revenue was Rs 4.77 lakh in Q4 FY26 versus Rs 2.97 lakh last year.
• 📊 Profit before tax was a loss of Rs 84.65 lakh in FY26 versus Rs 0.67 lakh loss last year.
• 📊 Profit after tax was a loss of Rs 84.65 lakh in FY26 versus Rs 0.67 lakh loss last year.
• 📊 Q4 FY26 PAT was a loss of Rs 45.68 lakh versus Rs 34.22 lakh loss last year.
• 📊 Basic and diluted EPS were Rs -16.93 for FY26 and Rs -9.1361 for Q4 FY26.

Expenses and balance sheet

• 📊 Other expenses were Rs 17.61 lakh in FY26 versus Rs 7.47 lakh last year.
• 📊 Finance costs were nil in FY26.
• 📊 Depreciation and amortisation expense was Rs 0.36 lakh in FY26.
• 📊 Cash and cash equivalents ended FY26 at Rs 3.29 lakh versus Rs 129.90 lakh last year.
• 📊 Net cash outflow from operating activities was Rs 470.10 lakh in FY26.

Resolution plan impact

• 📍 The NCLT-approved resolution plan was reflected in FY26 financial results.
• 📍 Existing public shareholding was reduced to 25,000 equity shares.
• 📍 50,000 equity shares were allotted to financial creditors.
• 📍 4,25,000 equity shares were allotted to the successful resolution applicant and promoter group.

Audit opinion

• 📍 Statutory auditors issued an unmodified opinion on the audited standalone FY26 results.

Business

• Dharti Proteins Limited reports standalone audited quarterly and annual results.
• The document reflects post-resolution-plan equity restructuring and share allotments.